Glovit-cal Dosage

• Dosage of Calcium (Glovit-cal) in details
• Calcium (Glovit-cal) interactions
• Dosage of Colecalciferol (Glovit-cal) in details
• Colecalciferol (Glovit-cal) interactions
• Dosage of Copper (Glovit-cal) in details
• Copper (Glovit-cal) interactions
• Dosage of Magnesium (Glovit-cal) in details
• Magnesium (Glovit-cal) interactions
• Dosage of Manganese (Glovit-cal) in details
• Manganese (Glovit-cal) interactions
• Dosage of Zinc (Glovit-cal) in details
• Zinc (Glovit-cal) interactions
• Glovit-cal reviews

Consists of Boron, Calcium, Colecalciferol, Copper, Magnesium, Manganese, Zinc

Dosage of Calcium (Glovit-cal) in details

Caplet Adult 1 caplet 1-2 times daily. Adolescent & childn >8 yr ½ caplet 1-2 times daily. Susp Childn 1-3 tsp once daily.

Calcium (Glovit-cal) interactions

*Major Interaction Do not take this combination

* Ceftriaxone (Rocephin) interacts with CALCIUM

Administering intravenous ceftriaxone and calcium can result in life-threatening damage to the lungs and kidneys. Calcium should not be administered intravenously within 48 hours of intravenous ceftriaxone.

*Moderate Interaction Be cautious with this combination

* Antibiotics (Quinolone antibiotics) interacts with CALCIUM

Calcium might decrease how much antibiotic your body absorbs. Taking calcium along with some antibiotics might decrease the effectiveness of some antibiotics. To avoid this interaction, take calcium supplements at least 1 hour after antibiotics.

Some of these antibiotics that might interact with calcium include ciprofloxacin (Cipro), enoxacin (Penetrex), norfloxacin (Chibroxin, Noroxin), sparfloxacin (Zagam), and trovafloxacin (Trovan).

* Antibiotics (Tetracycline antibiotics) interacts with CALCIUM

Calcium can attach to some antibiotics called tetracyclines in the stomach. This decreases the amount of tetracyclines that can be absorbed. Taking calcium with tetracyclines might decrease the effectiveness of tetracyclines. To avoid this interaction take calcium 2 hours before or 4 hours after taking tetracyclines.

Some tetracyclines include demeclocycline (Declomycin), minocycline (Minocin), and tetracycline (Achromycin, and others).

* Bisphosphonates interacts with CALCIUM

Calcium can decrease how much bisphosphate your body absorbs. Taking calcium along with bisphosphates can decrease the effectiveness of bisphosphate. To avoid this interaction, take bisphosphonate at least 30 minutes before calcium or later in the day.

Some bisphosphonates include alendronate (Fosamax), etidronate (Didronel), risedronate (Actonel), tiludronate (Skelid), and others.

* Calcipotriene (Dovonex) interacts with CALCIUM

Calcipotriene (Dovonex) is a drug that is similar to vitamin D. Vitamin D helps your body absorb calcium. Taking calcium supplements along with calcipotriene (Dovonex) might cause the body to have too much calcium.

* Digoxin (Lanoxin) interacts with CALCIUM

Calcium can affect your heart. Digoxin (Lanoxin) is used to help your heart beat stronger. Taking calcium along with digoxin (Lanoxin) might increase the effects of digoxin (Lanoxin) and lead to an irregular heartbeat. If you are taking digoxin (Lanoxin), talk to your doctor before taking calcium supplements.

* Diltiazem (Cardizem, Dilacor, Tiazac) interacts with CALCIUM

Calcium can affect your heart. Diltiazem (Cardizem, Dilacor, Tiazac) can also affect your heart. Taking large amounts of calcium along with diltiazem (Cardizem, Dilacor, Tiazac) might decrease the effectiveness of diltiazem (Cardizem, Dilacor, Tiazac).

* Levothyroxine interacts with CALCIUM

Levothyroxine is used for low thyroid function. Calcium can decrease how much levothyroxine your body absorbs. Taking calcium along with levothyroxine might decrease the effectiveness of levothyroxine. Levothyroxine and calcium should be taken at least 4 hours apart.

Some brands that contain levothyroxine include Armour Thyroid, Eltroxin, Estre, Euthyrox, Levo-T, Levothroid, Levoxyl, Synthroid, Unithroid, and others.

* Sotalol (Betapace) interacts with CALCIUM

Taking calcium with sotalol (Betapace) can decrease how much sotalol (Betapace) your body absorbs. Taking calcium along with sotalol (Betapace) might decrease the effectiveness of sotalol (Betapace). To avoid this interaction, take calcium at least 2 hours before or 4 hours after taking sotalol (Betapace).

* Verapamil (Calan, Covera, Isoptin, Verelan) interacts with CALCIUM

Calcium can affect your heart. Verapamil (Calan, Covera, Isoptin, Verelan) can also affect your heart. Do not take large amounts of calcium if you are taking verapamil (Calan, Covera, Isoptin, Verelan).

* Water pills (Thiazide diuretics) interacts with CALCIUM

Some "water pills" increase the amount of calcium in your body. Taking large amounts of calcium with some "water pills" might cause there to be too much calcium in the body. This could cause serious side effects, including kidney problems.

Some of these "water pills" include chlorothiazide (Diuril), hydrochlorothiazide (HydroDIURIL, Esidrix), indapamide (Lozol), metolazone (Zaroxolyn), and chlorthalidone (Hygroton).

*Minor Interaction Be watchful with this combination

* Estrogens interacts with CALCIUM

Estrogen helps your body absorb calcium. Taking estrogen pills along with large amounts of calcium might increase calcium in the body too much.

Estrogen pills include conjugated equine estrogens (Premarin), ethinyl estradiol, estradiol, and others.

* Medications for high blood pressure (Calcium channel blockers) interacts with CALCIUM

Some medications for high blood pressure affect calcium in your body. These medications are called calcium channel blockers. Getting calcium injections might decrease the effectiveness of these medications for high blood pressure.

Some medications for high blood pressure include nifedipine (Adalat, Procardia), verapamil (Calan, Isoptin, Verelan), diltiazem (Cardizem), isradipine (DynaCirc), felodipine (Plendil), amlodipine (Norvasc), and others.

Dosage of Colecalciferol (Glovit-cal) in details

1 or 2 tablets/day with main meal.

Administration: Swallow with a glass of water or a cold drink.

Not to be chewed.

Do not exceed recommended intake.

Colecalciferol (Glovit-cal) can be continued for as long as required.

What other drugs will affect Colecalciferol (Glovit-cal)?

Ask a doctor or pharmacist if it is safe for you to use cholecalciferol if you are also using any of the following drugs:

• seizure medication;

• cholestyramine, colestipol;

• steroids;

• digoxin; or

• a diuretic or "water pill."

This list is not complete. Other drugs may interact with cholecalciferol, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.

Colecalciferol (Glovit-cal) interactions

Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Colecalciferol (Glovit-cal))

Cholestyramine

Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins; as such it may impair intestinal absorption of any of vitamin D

Phenytoin/Phenobarbital

The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism. Since blood level of calcitriol/ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously

Thiazides

Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia. Therefore, precaution should be taken when coadministration is necessary

Digitalis

Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias

Ketoconazole

Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D. Reductions in serum endogenous vitamin D concentrations have been observed following the administration of 300 mg/day to 1200 mg/day ketoconazole for a week to healthy men. However, in vivo drug interaction studies of ketoconazole with vitamin D have not been investigated

Corticosteroids

A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption

Phosphate-Binding Agents

Since vitamin D also has an effect on phosphate transport in the intestine, kidneys and bones, the dosage of phosphate-binding agents must be adjusted in accordance with the serum phosphate concentration

Vitamin D

The coadministration of any of the vitamin D analogues should be avoided as this could create possible additive effects and hypercalcemia

Calcium Supplements

Uncontrolled intake of additional calcium-containing preparations should be avoided

Magnesium

Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.

Dosage of Copper (Glovit-cal) in details

Copper (Glovit-cal) 0.4 mg/mL (Cupric Chloride Injection, USP) contains 0.4 mg Copper (Glovit-cal)/mL and is administered intravenously only after dilution. The additive should be diluted in a volume of fluid not less than 100 mL. For the adult receiving TPN, the suggested additive dosage is 0.5 to 1.5 mg Copper (Glovit-cal)/day (1.25 to 3.75 mL/day). For pediatric patients, the suggested additive dosage is 20 mcg Copper (Glovit-cal)/kg/day (0.05 mL/kg/day). Infants weighing less than 1500 gm may have increased requirements because of their low body reserves and increased requirements for growth.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Copper (Glovit-cal) interactions

Ascorbic Acid: Copper (Glovit-cal) may decrease the serum concentration of Ascorbic Acid. Management: To minimize the risk for ascorbic acid degradation, add multivitamin product to TPN solution immediately prior to infusion or administer multivitamin and Copper (Glovit-cal) in separate containers. Consider therapy modification

Dosage of Magnesium (Glovit-cal) in details

Dosage of Magnesium (Glovit-cal) sulfate must be carefully adjusted according to individual requirements and response, and administration of the drug should be discontinued as soon as the desired effect is obtained.

Both intravenous and intramuscular administration are appropriate.

Intramuscular administration of the undiluted 50% solution results in therapeutic plasma levels in 60 minutes, whereas intravenous doses will provide a therapeutic level almost immediately. The rate of intravenous injection should generally not exceed 150 mg/minute (1.5 mL of a 10% concentration or its equivalent), except in severe eclampsia with seizures. Continuous maternal administration of Magnesium (Glovit-cal) sulfate in pregnancy beyond 5 to 7 days can cause fetal abnormalities.

Solutions for intravenous infusion must be diluted to a concentration of 20% or less prior to administration. The diluents commonly used are 5% Dextrose Injection, USP and 0.9% Sodium Chloride Injection, USP. Deep intramuscular injection of the undiluted (50%) solution is appropriate for adults, but the solution should be diluted to a 20% or less concentration prior to such injection in children.

In Magnesium (Glovit-cal) Deficiency

In the treatment of mild Magnesium (Glovit-cal) deficiency, the usual adult dose is 1 gram, equivalent to 8.12 mEq of Magnesium (Glovit-cal) (2 mL of the 50% solution) injected intramuscularly every six hours for four doses (equivalent to a total of 32.5 mEq of Magnesium (Glovit-cal) per 24 hours). For severe hypomagnesemia, as much as 250 mg (approximately 2 mEq) per kg of body weight (0.5 mL of the 50% solution) may be given intramuscularly within a period of four hours if necessary. Alternatively, 5 grams, (approximately 40 mEq) can be added to one liter of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP for slow intravenous infusion over a three-hour period. In the treatment of deficiency states, caution must be observed to prevent exceeding the renal excretory capacity.

In Hyperalimentation

In total parenteral nutrition, maintenance requirements for Magnesium (Glovit-cal) are not precisely known. The maintenance dose used in adults ranges from 8 to 24 mEq (1 gram to 3 grams) daily; for infants, the range is 2 to 10 mEq (0.25 gram to 1.25 grams) daily.

In Pre-eclampsia or Eclampsia

In severe pre-eclampsia or eclampsia, the total initial dose is 10 grams to 14 grams of Magnesium (Glovit-cal) sulfate.

Intravenously, a dose of 4 grams to 5 grams in 250 mL of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP may be infused. Simultaneously, intramuscular doses of up to 10 grams (5 grams or 10 mL of the undiluted 50% solution in each buttock) are given. Alternatively, the initial intravenous dose of 4 grams may be given by diluting the 50% solution to a 10 or 20% concentration; the diluted fluid (40 mL of a 10% solution or 20 mL of a 20% solution) may then be injected intravenously over a period of three to four minutes. Subsequently, 4 grams to 5 grams (8 to 10 mL of the 50% solution) are injected intramuscularly into alternate buttocks every four hours as needed, depending on the continuing presence of the patellar reflex and adequate respiratory function. Alternatively, after the initial intravenous dose, some clinicians administer 1 gram to 2 grams/hour by constant intravenous infusion. Therapy should continue until paroxysms cease. A serum Magnesium (Glovit-cal) level of 6 mg/100 mL is considered optimal for control of seizures. A total daily (24 hr) dose of 30 grams to 40 grams should not be exceeded. In the presence of severe renal insufficiency, the maximum dosage of Magnesium (Glovit-cal) sulfate is 20 grams/48 hours and frequent serum Magnesium (Glovit-cal) concentrations must be obtained. Continuous use of Magnesium (Glovit-cal) sulfate in pregnancy beyond 5 to 7 days can cause fetal abnormalities.

Other Uses

In counteracting the muscle-stimulating effects of barium poisoning, the usual dose of Magnesium (Glovit-cal) sulfate is 1 gram to 2 grams given intravenously.

For controlling seizures associated with epilepsy, glomerulonephritis or hypothyroidism, the usual adult dose is 1 gram administered intramuscularly or intravenously.

In paroxysmal atrial tachycardia, Magnesium (Glovit-cal) should be used only if simpler measures have failed and there is no evidence of myocardial damage. The usual dose is 3 grams to 4 grams (30 to 40 mL of a 10% solution) administered intravenously over 30 seconds with extreme caution.

For reduction of cerebral edema, 2.5 grams (25 mL of a 10% solution) is given intravenously.

Incompatibilities

Magnesium (Glovit-cal) sulfate in solution may result in a precipitate formation when mixed with solutions containing:

Alcohol (in high Heavy Metals

concentrations) Hydrocortisone sodium

Alkali carbonates and succinate

bicarbonates Phosphates

Alkali hydroxides Polymixin B sulfate

Arsenates Procaine hydrochloride

Barium Salicylates

Calcium Strontium

Clindamycin phosphate Tartrates

The potential incompatibility will often be influenced by the changes in the concentration of reactants and the pH of the solutions.

It has been reported that Magnesium (Glovit-cal) may reduce the antibiotic activity of streptomycin, tetracycline and tobramycin when given together.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

What other drugs will affect Magnesium (Glovit-cal)?

Certain antibiotics should not be taken at the same time as Magnesium (Glovit-cal) gluconate because they may not be absorbed as well by your body. If you are taking an antibiotic, avoid taking it within 2 hours before or after you take Magnesium (Glovit-cal) gluconate.

Before taking Magnesium (Glovit-cal) gluconate, tell your doctor if you are using any of the following drugs:

• naladixic acid (NegGram);

• penicillamine (Cuprimine, Depen);

• an antibiotic such as tetracycline (Brodspec, Sumycin, Tetracap, and others), demeclocycline (Declomycin), doxycycline (Vibramycin, Monodox, Doryx, Doxy, and others), or minocycline (Minocin, Dynacin, and others);

• a fluoroquinolone antibiotic such as ciprofloxacin (Cipro), gatifloxacin (Tequin), levofloxacin (Levaquin), lomefloxacin (Maxaquin), moxifloxacin (Avelox), norfloxacin (Noroxin), ofloxacin (Floxin), sparfloxacin (Zagam), or trovafloxacin (Trovan); or

• a medication for osteoporosis or Paget's disease, such as alendronate (Fosamax), etidronate (Didronel), ibandronate (Boniva), risedronate (Actonel), or tiludronate (Skelid).

If you are using any of these drugs, you may not be able to use Magnesium (Glovit-cal) gluconate, or you may need dosage adjustments or special tests during treatment.

There may be other drugs not listed that can affect Magnesium (Glovit-cal) gluconate. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.

Magnesium (Glovit-cal) interactions

Alfacalcidol: May increase the serum concentration of Magnesium (Glovit-cal) Salts. Consider therapy modification

Alpha-Lipoic Acid: Magnesium (Glovit-cal) Salts may decrease the absorption of Alpha-Lipoic Acid. Alpha-Lipoic Acid may decrease the absorption of Magnesium (Glovit-cal) Salts. Consider therapy modification

Baloxavir Marboxil: Polyvalent Cation Containing Products may decrease the serum concentration of Baloxavir Marboxil. Avoid combination

Bictegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Bictegravir. Management: Administer bictegravir under fasting conditions at least 2 hours before or 6 hours after polyvalent cation containing products. Coadministration of bictegravir with or 2 hours after most polyvalent cation products is not recommended. Consider therapy modification

Bisphosphonate Derivatives: Polyvalent Cation Containing Products may decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral medications containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate. Exceptions: Pamidronate; Zoledronic Acid. Consider therapy modification

Calcitriol (Systemic): May increase the serum concentration of Magnesium (Glovit-cal) Salts. Management: Consider using a non-Magnesium (Glovit-cal)-containing antacid or phosphate-binding product in patients also receiving calcitriol. If Magnesium (Glovit-cal)-containing products must be used with calcitriol, serum Magnesium (Glovit-cal) concentrations should be monitored closely. Consider therapy modification

Calcium Channel Blockers: May enhance the adverse/toxic effect of Magnesium (Glovit-cal) Salts. Magnesium (Glovit-cal) Salts may enhance the hypotensive effect of Calcium Channel Blockers. Monitor therapy

Deferiprone: Polyvalent Cation Containing Products may decrease the serum concentration of Deferiprone. Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours. Consider therapy modification

Dolutegravir: Magnesium (Glovit-cal) Salts may decrease the serum concentration of Dolutegravir. Management: Administer dolutegravir at least 2 hours before or 6 hours after oral Magnesium (Glovit-cal) salts. Administer the dolutegravir/rilpivirine combination product at least 4 hours before or 6 hours after oral Magnesium (Glovit-cal) salts. Consider therapy modification

Doxercalciferol: May enhance the hypermagnesemic effect of Magnesium (Glovit-cal) Salts. Management: Consider using a non-Magnesium (Glovit-cal)-containing antacid or phosphate-binding product in patients also receiving doxercalciferol. If Magnesium (Glovit-cal)-containing products must be used with doxercalciferol, serum Magnesium (Glovit-cal) concentrations should be monitored closely. Consider therapy modification

Eltrombopag: Polyvalent Cation Containing Products may decrease the serum concentration of Eltrombopag. Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any polyvalent cation containing product. Consider therapy modification

Elvitegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Elvitegravir. Management: Administer elvitegravir 2 hours before or 6 hours after the administration of polyvalent cation containing products. Consider therapy modification

Gabapentin: Magnesium (Glovit-cal) Salts may enhance the CNS depressant effect of Gabapentin. Specifically, high dose intravenous/epidural Magnesium (Glovit-cal) sulfate may enhance the CNS depressant effects of gabapentin. Magnesium (Glovit-cal) Salts may decrease the serum concentration of Gabapentin. Management: Administer gabapentin at least 2 hours after use of a Magnesium (Glovit-cal)-containing antacid. Monitor patients closely for evidence of reduced response to gabapentin therapy. Monitor for CNS depression if high dose IV/epidural Magnesium (Glovit-cal) sulfate is used. Consider therapy modification

Levothyroxine: Magnesium (Glovit-cal) Salts may decrease the serum concentration of Levothyroxine. Management: Separate administration of oral levothyroxine and oral Magnesium (Glovit-cal) salts by at least 4 hours. Consider therapy modification

Multivitamins/Fluoride (with ADE): Magnesium (Glovit-cal) Salts may decrease the serum concentration of Multivitamins/Fluoride (with ADE). Specifically, Magnesium (Glovit-cal) salts may decrease fluoride absorption. Management: To avoid this potential interaction separate the administration of Magnesium (Glovit-cal) salts from administration of a fluoride-containing product by at least 1 hour. Consider therapy modification

Mycophenolate: Magnesium (Glovit-cal) Salts may decrease the serum concentration of Mycophenolate. Management: Separate doses of mycophenolate and oral Magnesium (Glovit-cal) salts. Monitor for reduced effects of mycophenolate if taken concomitant with oral Magnesium (Glovit-cal) salts. Consider therapy modification

Neuromuscular-Blocking Agents: Magnesium (Glovit-cal) Salts may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Monitor therapy

PenicillAMINE: Polyvalent Cation Containing Products may decrease the serum concentration of PenicillAMINE. Management: Separate the administration of penicillamine and oral polyvalent cation containing products by at least 1 hour. Consider therapy modification

Phosphate Supplements: Magnesium (Glovit-cal) Salts may decrease the serum concentration of Phosphate Supplements. Management: Administer oral phosphate supplements as far apart from the administration of an oral Magnesium (Glovit-cal) salt as possible to minimize the significance of this interaction. Exceptions: Sodium Glycerophosphate Pentahydrate. Consider therapy modification

Quinolones: Magnesium (Glovit-cal) Salts may decrease the serum concentration of Quinolones. Management: Administer oral quinolones several hours before (4 h for moxi/pe/spar-, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome/pe-, 3 h for gemi-, and 2 h for levo-, nor-, or ofloxacin or nalidixic acid) oral Magnesium (Glovit-cal) salts. Exceptions: LevoFLOXacin (Oral Inhalation). Consider therapy modification

Raltegravir: Magnesium (Glovit-cal) Salts may decrease the serum concentration of Raltegravir. Management: Avoid the use of oral / enteral Magnesium (Glovit-cal) salts with raltegravir. No dose separation schedule has been established that adequately reduces the magnitude of interaction. Avoid combination

Tetracyclines: Magnesium (Glovit-cal) Salts may decrease the absorption of Tetracyclines. Only applicable to oral preparations of each agent. Management: Avoid coadministration of oral Magnesium (Glovit-cal) salts and oral tetracyclines. If coadministration cannot be avoided, administer oral Magnesium (Glovit-cal) at least 2 hours before, or 4 hours after, oral tetracyclines. Monitor for decreased tetracycline therapeutic effects. Exceptions: Eravacycline. Consider therapy modification

Trientine: Polyvalent Cation Containing Products may decrease the serum concentration of Trientine. Management: Avoid concomitant administration of trientine and oral products that contain polyvalent cations. If oral iron supplements are required, separate the administration by 2 hours. If other oral polyvalent cations are needed, separate administration by 1 hour. Consider therapy modification

Dosage of Manganese (Glovit-cal) in details

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Capsule,

Oral, as chelated:

MN-50: Elemental Manganese (Glovit-cal) 16.67 mg

Solution,

Intravenous, as chloride:

Generic: Elemental Manganese (Glovit-cal) 0.1 mg/mL (10 mL)

Solution,

Intravenous, as sulfate [preservative free]:

Generic: Elemental Manganese (Glovit-cal) 0.1 mg/mL (10 mL)

Tablet,

Oral, as aspartate:

Generic: 93 mg [elemental Manganese (Glovit-cal) 25 mg]

Tablet,

Oral, as chelated:

Mangimin: Elemental Manganese (Glovit-cal) 10 mg [corn free, rye free, wheat free]

Generic: Elemental Manganese (Glovit-cal) 15 mg [DSC], Elemental Manganese (Glovit-cal) 50 mg

Tablet,

Oral, as gluconate:

Generic: 50 mg [elemental Manganese (Glovit-cal) 5.7 mg]

Dosing: Adult

Parenteral nutrition, maintenance requirement:

Expert recommendations favor the use of lower doses in the range of 60 to 100 mcg/day to avoid neurotoxicity with routine use and those with cholestatic jaundice. However, these recommendations are difficult to follow with the current sources of parenteral Manganese (Glovit-cal) (ASPEN [Vanek 2012]).

Dosing: Geriatric

Refer to adult dosing.

Dosing: Pediatric

Parenteral nutrition, maintenance requirement:

Expert recommendations suggest decreasing the daily dose for infants and children to 1 mcg/kg/day (up to a maximum of 50 mcg/day). However, these recommendations are difficult to follow with the current sources of parenteral Manganese (Glovit-cal) (ASPEN [Vanek 2012]).

Note: Use caution in premature neonates; Manganese (Glovit-cal) chloride solution for injection contains aluminum.

Manganese (Glovit-cal) interactions

There are no known significant interactions.

Dosage of Zinc (Glovit-cal) in details

Zinc (Glovit-cal) 1 mg/mL (Zinc (Glovit-cal) Chloride Injection, USP) contains 1 mg Zinc (Glovit-cal)/mL and is administered intravenously only after dilution. The additive should be diluted prior to administration in a volume of fluid not less than 100 mL. For the metabolically stable adult receiving TPN, the suggested intravenous dosage is 2.5 to 4 mg Zinc (Glovit-cal)/day (2.5 to 4 mL/day). An additional 2 mg Zinc (Glovit-cal)/day (2 mL/day) is suggested for acute catabolic states. For the stable adult with fluid loss from the small bowel, an additional 12.2 mg Zinc (Glovit-cal)/liter of small bowel fluid lost (12.2 mL/liter of small bowel fluid lost), or an additional 17.1 mg Zinc (Glovit-cal)/kg of stool or ileostomy output (17.1 mL/kg of stool or ileostomy output) is recommended. Frequent monitoring of Zinc (Glovit-cal) blood levels is suggested for patients receiving more than the usual maintenance dosage level of Zinc (Glovit-cal).

For full term infants and children up to 5 years of age, 100 mcg Zinc (Glovit-cal)/kg/day

(0.1 mL/kg/day) is recommended. For premature infants (birth weight less than 1500 g) up to 3 kg in body weight, 300 mcg Zinc (Glovit-cal)/kg/day (0.3 mL/kg/day) is suggested.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. See PRECAUTIONS.

How supplied

Zinc (Glovit-cal) 1 mg/mL (Zinc (Glovit-cal) Chloride Injection, USP) is supplied in 10 mL Plastic Vials (List No. 4090).

Store at 20 to 25°C (68 to 77°F).

HOSPIRA, INC., LAKE FOREST, IL 60045 USA. Revised: October, 2004

What other drugs will affect Zinc (Glovit-cal)?

Other drugs may interact with Zinc (Glovit-cal) sulfate, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell each of your health care providers about all medicines you use now and any medicine you start or stop using.

Zinc (Glovit-cal) interactions

Pyridoxine reduces the effects of levodopa (but this does not occur if a dopa decarboxylase is also given); decreases serum concentrations of phenobarbitone. Concurrent administration of drugs eg, isoniazid, penicillamine and oral contraceptives increase the requirement for pyridoxine.

Absorption of cyanocobalamin from the GIT may be reduced by neomycin, aminosalicylic acid, histamine H₂-receptor antagonists and colchicine. Serum concentrations may be decreased by concurrent administration of oral contraceptives. Many of these interactions are unlikely to be of clinical significance but should be taken into account when performing assays for blood concentrations.

Parenteral chloramphenicol may attenuate the effect of vitamin B12 in anaemia.

Folate deficiency states may be produced by a number of drugs including antiepileptics, oral contraceptives, antituberculous drugs, alcohol and folic acid antagonists eg, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides; folic acid may decrease serum-phenytoin concentrations.

There may be an increased risk of myopathy or rhabdomyolysis when nicotinic acid is used concurrently with statins. Nicotinamide may increase the requirements for insulin or oral hypoglycaemics.

Ascorbic acid may increase the absorption of iron-deficiency states.

Ascorbic acid is often given in addition to desferrioxamine to patients with iron overload (thalassemia) to achieve better iron excretion. However, early on in treatment when there is excess tissue iron, there is some evidence that ascorbic acid may worsen the iron toxicity, particularly to the heart. Thus, ascorbic acid should not be given for the first month after starting desferrioxamine treatment.

The absorption of Zinc (Glovit-cal) may be reduced by iron supplements, penicillamine, phosphorus-containing preparations and tetracyclines. Zinc (Glovit-cal) supplements reduce the absorption of Zinc (Glovit-cal), ciprofloxacin, iron, norfloxacin, penicillamine and tetracyclines.

References

1. DailyMed. "COPPER: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
2. DailyMed. "CALCIUM: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
3. FDA/SPL Indexing Data. "SY7Q814VUP: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).

Reviews

User reports

Consumer reviews

Information checked by Dr. Sachin Kumar, MD Pharmacology